domenica, 24 ottobre 2021
Medinews
26 Agosto 2016

La Commissione Europea approva pembrolizumab per il trattamento del NSCLC positivo a PD-L1

The European Commission (EC) has approved pembrolizumab (Keytruda) as a treatment for patients with locally advanced or metastatic PD-L1–positive non–small cell lung cancer (NSCLC) following at least 1 chemotherapy regimen, according to Merck, the manufacturer of the PD-1 inhibitor. The approval stipulates that patients whose tumors are EGFR or ALK positive should first receive an EFGR or ALK inhibitor, respectively, prior to treatment with pembrolizumab. The approved dose for the anti–PD-1 agent is 2 mg/kg every 3 weeks. The EC’s decision, which was primarily based on … (leggi tutto)

TORNA INDIETRO